Combined vaccine+axitinib therapy yields superior antitumor efficacy in a murine melanoma model

Stat6 Signaling Suppresses VLA-4 Expression by CD8+ T Cells and Limits Their Ability to Infiltrate Tumor Lesions In Vivo

(2014) K. Sasaki et al.   JOURNAL OF IMMUNOLOGY

Vaccines Targeting Tumor Blood Vessel Antigens Promote CD8+ T Cell-Dependent Tumor Eradication or Dormancy in HLA-A2 Transgenic Mice

(2012) X. Zhao et al.   JOURNAL OF IMMUNOLOGY

Chronic exposure of colorectal cancer cells to bevacizumab promotes compensatory pathways that mediate tumour cell migration

(2011) F Fan et al.   BRITISH JOURNAL OF CANCER

DLL4-Notch Signaling Mediates Tumor Resistance to Anti-VEGF Therapy In Vivo

(2011) J.-L. Li et al.   CANCER RESEARCH

SKLB1002, a Novel Potent Inhibitor of VEGF Receptor 2 Signaling, Inhibits Angiogenesis and Tumor Growth In Vivo

(2011) S. Zhang et al.   CLINICAL CANCER RESEARCH

Diastolic Blood Pressure as a Biomarker of Axitinib Efficacy in Solid Tumors

(2011) B. I. Rini et al.   CLINICAL CANCER RESEARCH

Multicenter, Phase II Study of Axitinib, a Selective Second-Generation Inhibitor of Vascular Endothelial Growth Factor Receptors 1, 2, and 3, in Patients with Metastatic Melanoma

(2011) J. Fruehauf et al.   CLINICAL CANCER RESEARCH

Regulatory T cells and Foxp3

(2011) Alexander Y. Rudensky   IMMUNOLOGICAL REVIEWS

Hypertension as a Biomarker of Efficacy in Patients With Metastatic Renal Cell Carcinoma Treated With Sunitinib

(2011) B. I. Rini et al.   JNCI-Journal of the National Cancer Institute

Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial

(2011) Brian I Rini et al.   LANCET

Normalization of the Vasculature for Treatment of Cancer and Other Diseases

(2011) Shom Goel et al.   PHYSIOLOGICAL REVIEWS

Bevacizumab and everolimus in the treatment of patients with metastatic melanoma

(2010) John D. Hainsworth et al.   CANCER

Antiangiogenic Agents Can Increase Lymphocyte Infiltration into Tumor and Enhance the Effectiveness of Adoptive Immunotherapy of Cancer

(2010) R. K. Shrimali et al.   CANCER RESEARCH

Bevacizumab plus Fotemustine as First-line Treatment in Metastatic Melanoma Patients: Clinical Activity and Modulation of Angiogenesis and Lymphangiogenesis Factors

(2010) M. Del Vecchio et al.   CLINICAL CANCER RESEARCH

The biology of myeloid-derived suppressor cells: The blessing and the curse of morphological and functional heterogeneity

(2010) Je-In Youn et al.   EUROPEAN JOURNAL OF IMMUNOLOGY

Sunitinib facilitates the activation and recruitment of therapeutic anti-tumor immunity in concert with specific vaccination

(2010) Anamika Bose et al.   INTERNATIONAL JOURNAL OF CANCER

Gene therapy using genetically modified lymphocytes targeting VEGFR-2 inhibits the growth of vascularized syngenic tumors in mice

(2010) Dhanalakshmi Chinnasamy et al.   JOURNAL OF CLINICAL INVESTIGATION

Resistance to antiangiogenic therapy is directed by vascular phenotype, vessel stabilization, and maturation in malignant melanoma

(2010) Iris Helfrich et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Intralesional Delivery of Dendritic Cells Engineered to Express T-bet Promotes Protective Type 1 Immunity and the Normalization of the Tumor Microenvironment

(2010) Y. Qu et al.   JOURNAL OF IMMUNOLOGY

A phase II trial of bevacizumab with dacarbazine and daily low-dose interferon-α2a as first line treatment in metastatic melanoma

(2010) Pia P. Vihinen et al.   MELANOMA RESEARCH

Intratumoral IL-12 Gene Therapy Results in the Crosspriming of Tc1 Cells Reactive Against Tumor-associated Stromal Antigens

(2010) Xi Zhao et al.   MOLECULAR THERAPY

A phase I study of axitinib (AG-013736) in combination with bevacizumab plus chemotherapy or chemotherapy alone in patients with metastatic colorectal cancer and other solid tumors

(2009) S. Sharma et al.   ANNALS OF ONCOLOGY

Arterial hypertension correlates with clinical outcome in colorectal cancer patients treated with first-line bevacizumab

(2008) M. Scartozzi et al.   ANNALS OF ONCOLOGY

Inhibition of Multiple Vascular Endothelial Growth Factor Receptors (VEGFR) Blocks Lymph Node Metastases but Inhibition of VEGFR-2 Is Sufficient to Sensitize Tumor Cells to Platinum-Based Chemotherapeutics

(2008) P. Sini et al.   CANCER RESEARCH

CD8+ T-Cell Responses against Hemoglobin-  Prevent Solid Tumor Growth

(2008) H. Komita et al.   CANCER RESEARCH

Nonclinical Antiangiogenesis and Antitumor Activities of Axitinib (AG-013736), an Oral, Potent, and Selective Inhibitor of Vascular Endothelial Growth Factor Receptor Tyrosine Kinases 1, 2, 3

(2008) D. D. Hu-Lowe et al.   CLINICAL CANCER RESEARCH